Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function.
The effect of imipramine on symptomatic peripheral diabetic neuropathy in 9 patients was examined in a double-blind cross-over study against placebo. The dose of imipramine was adjusted to yield optimal plasma levels of imipramine plus desipramine of 300-750 nM. Imipramine had a clear beneificial effect on the symptoms of the neuropathy, whereas no changes in a range of neurophysiological measurement was detected. Despite some adverse effects, especially of an anticholinergic nature, the patients generally preferred imipramine to placebo.
Sindrup
S H
SH
Department of Internal Medicine, Fredericia Hospital, Denmark.
Ejlertsen
B
B
Frøland
A
A
Sindrup
E H
EH
Brøsen
K
K
Gram
L F
LF
D000328:Adult; D001341:Autonomic Nervous System / Q000187:drug effects*; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010525:Peripheral Nerves / Q000187:drug effects*
D007099:Imipramine